Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Amid FDA Approval Filings, Another CAR-T Therapy Patient Death.

Literature DB >> 28609515

Amid FDA Approval Filings, Another CAR-T Therapy Patient Death.

Jennifer Abbasi.

Abstract

Entities: Species

Mesh：

Substances：

Year: 2017 PMID： 28609515 DOI： 10.1001/jama.2017.7153

Source DB: PubMed Journal: JAMA ISSN： 0098-7484 Impact factor: 56.272

Keyword Cloud
Cited

× No keyword cloud information.

9 in total

Review 1. Are CAR T cells better than antibody or HCT therapy in B-ALL?

Authors: Michael A Pulsipher
Journal: Hematology Am Soc Hematol Educ Program Date: 2018-11-30

Review 2. Cellular therapy: Immune-related complications.

Authors: Joseph H Oved; David M Barrett; David T Teachey
Journal: Immunol Rev Date: 2019-07 Impact factor: 12.988

3. Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.

Authors: Matthew C Foster; Barbara Savoldo; Winnie Lau; Clio Rubinos; Natalie Grover; Paul Armistead; James Coghill; Robert S Hagan; Kaitlin Morrison; Faith Brianne Buchanan; Catherine Cheng; Spencer Laing; Anastasia Ivanova; John West; Aaron Foster; Jonathan Serody; Gianpietro Dotti
Journal: Blood Date: 2021-06-10 Impact factor: 25.476

Review 4. DNT Cell-based Immunotherapy: Progress and Applications.

Authors: Yingrui Li; Kang Dong; Xueke Fan; Jun Xie; Miao Wang; Songtao Fu; Qin Li
Journal: J Cancer Date: 2020-03-31 Impact factor: 4.207

5. Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia.

Authors: Furun An; Huiping Wang; Zhenyun Liu; Fan Wu; Jiakui Zhang; Qianshan Tao; Yingwei Li; Yuanyuan Shen; Yanjie Ruan; Qing Zhang; Ying Pan; Weiwei Zhu; Hui Qin; Yansheng Wang; Yongling Fu; Zhenqing Feng; Zhimin Zhai
Journal: Nat Commun Date: 2020-11-23 Impact factor: 14.919

Amid FDA Approval Filings, Another CAR-T Therapy Patient Death.

Review 1. Are CAR T cells better than antibody or HCT therapy in B-ALL?

Review 2. Cellular therapy: Immune-related complications.

3. Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.

Review 4. DNT Cell-based Immunotherapy: Progress and Applications.

5. Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia.

Review 6. Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.

Review 7. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy.

Review 8. Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.

Review 9. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.